Table 1

Baseline demographics of patients enrolled in this clinical trial


Patients given various daily doses of rhIL-11


Characteristics
 Patients given placebo
 2 × 2.5 μg/kg
 1 × 5 μg/kg
 2 × 7.5 μg/kg
 1 × 15 μg/kg
Number of patients
 19
 19
 17
 16
 20
Age (years)
 49.6
 51.8
 57.4
 49.4
 48.7
Sex (%)




     Male
 32
 16
 18
 44
 25
     Female
 68
 84
 82
 56
 75
Race (%)




     Black
 5
 11
 0
 13
 5
     Asian
 0
 0
 12
 0
 0
     Other
 0
 0
 6
 0
 0
     Hispanic
 11
 11
 6
 13
 10
     White
 84
 79
 76
 75
 85
Duration of disease (% of patients)




     <2 years
 0
 5
 6
 13
 15
     2-5 years
 26
 21
 24
 19
 20
     >5 years
 74
 74
 71
 69
 65
Measures of arthritis activity




     Swollen-joint counta
 24 ± 11
 20 ± 10
 21 ± 10
 17 ± 10
 21 ± 10
     Tender-joint counta
 33 ± 13
 29 ± 13
 32 ± 16
 26 ± 12
 26 ± 13
     Total counta
 57 ± 18
 49 ± 22
 54 ± 24
 43 ± 21
 46 ± 22
     Physician's assessmentb
 5.2
 4.7
 5.4
 4.9
 5.0
     Patient's assessmentb
 4.9
 4.4
 5.1
 5.0
 4.8
     Patient's pain
 4.6
 4.1
 5.4
 5.3
 4.8
     HAQc
 1.4
 1.3
 1.5
 1.4
 1.4
     C-reactive protein
 4.8
 4.4
 7.9
 5.2
 3.7

aValues are means ± SD. b1 is best and 7 is worst. cHAQ = health assessment questionnaire; 0 is best and 3 is worst.

Moreland et al. Arthritis Res 2001 3:247   doi:10.1186/ar309

Open Data